title: Immunohistochemical localization of pancreatic secretory trypsin inhibitor in malignant pancreatic endocrine tumors.
abstract: Differentiation of benign from malignant pancreatic endocrine tumors by existing clinical, biochemical, histologic, and cytologic criteria is difficult. We immunohistochemically localized pancreatic secretory trypsin inhibitor (PSTI) in 28 pancreatic endocrine tumors (13 benign, 15 malignant). PSTI-immunoreactive cells were detected in nine endocrine tumors. Immunoreactivity in these tumors was detected in nearly all tumor cells in five cases, scattered cells in two cases, and a few cells in two cases. All positive cases were malignant, and eight were equal to or larger than 10 cm. Serum concentrations of PSTI were markedly elevated in the two patients so tested. PSTI may be a specific immunohistochemical marker for malignant pancreatic endocrine tumors.
authors.affiliation: Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kamisawa
authors.forename: Y
authors.initials: Y
authors.lastname: Tu
authors.forename: N
authors.initials: N
authors.lastname: Egawa
authors.forename: J
authors.initials: J
authors.lastname: Ishiwata
authors.forename: K
authors.initials: K
authors.lastname: Tsuruta
authors.forename: A
authors.initials: A
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: M
authors.initials: M
authors.lastname: Koike
mesh_terms: D000328:Adult; D000681:Amylases / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D021441:Carcinoma, Pancreatic Ductal / Q000737:chemistry* / Q000145:classification / Q000648:ultrastructure; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D004273:DNA, Neoplasm / Q000032:analysis; D005935:Glucagonoma / Q000737:chemistry* / Q000648:ultrastructure; D006801:Humans; D007124:Immunoenzyme Techniques; D007340:Insulinoma / Q000737:chemistry* / Q000648:ultrastructure; D019394:Ki-67 Antigen / Q000032:analysis; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis*; D010196:Pancreatic Elastase / Q000032:analysis; D010187:Pancreatic Hormones / Q000032:analysis; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000648:ultrastructure; D010191:Pancreatic Polypeptide / Q000032:analysis; D016612:Paraffin Embedding; D012701:Serotonin / Q000032:analysis; D016708:Synaptophysin / Q000032:analysis; D014357:Trypsin / Q000032:analysis; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D010187:Pancreatic Hormones; D016708:Synaptophysin; D012701:Serotonin; D014359:Trypsin Inhibitor, Kazal Pancreatic; D010191:Pancreatic Polypeptide; D000681:Amylases; D010196:Pancreatic Elastase; D014357:Trypsin